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DOI 10.1016/j.ccr.2010.09.008SUMMARYAlthough myeloid leukemias are primarily caused by leukemic stem cells, the molecular basis of their trans-
formation remains largely unknown. Here, by analyzing mice with a mutation in the RING finger domain of
c-Cbl, we show that the E3 ubiquitin ligase activity of c-Cbl is required to restrict myeloid leukemia develop-
ment. These mice develop a myeloproliferative disease which progresses to leukemia and involves hemato-
poietic progenitors that exhibit augmented FLT3 signaling. Suppressing this signaling through matings with
FLT3 ligand knockout mice prevents leukemia development. We also observe enhanced c-Kit, Akt and Erk
activity, and deregulated expression of leukemia-associated transcription factors in hematopoietic progen-
itors. The characterization of these perturbations provides direction for therapeutics that may aid the treat-
ment of patients with c-Cbl mutations.INTRODUCTION
c-Cbl (Casitas B cell lymphoma), the cellular homolog of the
v-Cbl oncogene (Langdon et al., 1989), encodes a RING finger-
based E3 ubiquitin ligase that negatively regulates the activity
of many signaling pathways (Thien and Langdon, 2005). This
regulation is achieved by targeting an array of growth factor
receptors, antigen receptors, and protein tyrosine kinases,
thereby directing their polyubiquitylation and degradation. c-Cbl
also functions as a multidomain adaptor that recruits signaling
proteins such as phosphatidylinositol 3-kinase (PI3K) and Crk.
Indeed c-Cbl is probably themost extensively studied E3 ubiqui-
tin ligase and has been shown to be involved in the regulation of
150 cellular proteins, either directly or indirectly (Schmidt and
Dikic, 2005).
Although the biochemistry of c-Cbl’s E3 ligase activity and its
molecular interactions have been well characterized, the in vivo
roles of c-Cbl in hematopoiesis and leukemogenesis remain
elusive. Understanding this has become increasingly important
with the widespread involvement of mutated forms of c-Cbl in
human myeloproliferative neoplasms (MPNs) (Dunbar et al.,Significance
The c-Cbl proto-oncogene is mutated in a wide range of huma
RING finger mutant mouse, we show that the E3 ubiquitin liga
eration and the development of leukemia. This mouse therefo
associated leukemogenesis and the identification of cooperat
an avenue for testing the efficacy of therapeutic agents that t
c-Cbl.
C2008; Grand et al., 2009; Loh et al., 2009; Makishima et al.,
2009; Muramatsu et al., 2010; Sanada et al., 2009). Patients
examined to date number approximately 1800 and the MPNs
include myelodysplastic syndromes (MDS) and MDS/myelopro-
liferative disease (MPD) overlap entities chronic myelomonocytic
leukemia (CMML) and juvenile myelomonocytic leukemia
(JMML), atypical chronic myeloid leukemia, myelofibrosis, and
secondary acute myeloid leukemia (AML). The incidence of
c-Cbl mutations inMPDs is between 5%and 15%,with the high-
est rates occurring in CMML and JMML (for review, see Kales
et al., 2010; Ogawa et al., 2010). These studies relied on single
nucleotide polymorphism (SNP) array karyotyping to detect
regions of acquired uniparental disomy (aUPD), a somatic chro-
mosomal aberration that results in copy-neutral loss of heterozy-
gosity (Maciejewski et al., 2009). A common region of aUPD was
found to involve chromosome 11q focusing attention on c-Cbl
which is located at 11q23.3. DNA sequencing showed that
80%–100% of patients with 11q aUPD carried homozygous
c-Cbl mutations located in, or spanning, the linker and RING
finger domains that are essential for interactions with E2 ubiqui-
tin conjugating enzymes (Zheng et al., 2000).n myeloproliferative neoplasms. Through analysis of a c-Cbl
se activity of c-Cbl is critical for suppressing myeloid prolif-
re provides a model for studying the progression of c-Cbl-
ive mutations. Furthermore, this preclinical model provides
arget signaling molecules activated by oncogenic forms of
ancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc. 341
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c-Cbl and Myeloid LeukemiaRecently, we found c-Cbl to be highly expressed in hemato-
poietic stem cells (HSCs) and, through the analysis of c-Cbl
mutant mice, identified c-Cbl to be a critical negative regulator
of HSC function (Rathinam et al., 2008; Yokomizo and Dzierzak,
2008). These observations suggest that perturbations affecting
this regulatory role could promote the development of hemato-
poietic neoplasms. Here, we test this possibility by examining
knockin mice with loss-of-function mutations in the RING finger
domains of c-Cbl and Cbl-b, a homolog with a high level of iden-
tity to c-Cbl (Oksvold et al., 2008; Thien et al., 2005). The muta-
tion in thesemice is a substitution of an alanine for the N-terminal
cysteine in the C3HC4 RING domain, positioned at 379 in c-Cbl
(i.e., C379A) and 373 in Cbl-b (i.e., C373A), that disrupts the
interaction with E2 conjugating enzymes therefore abolishing
E3 ubiquitin ligase activity. In this study, we examined c-Cbl
and Cbl-b RING finger knockin mice, and their respective knock-
outs, to determine whether any of these mutations promote the
development of hematopoietic neoplasms.
RESULTS
MPD in Young c-Cbl Mutant Mice
To understand the functions of Cbl proteins in hematopoiesis
and leukemogenesis, wemade use of c-Cbl andCbl-b knockout-
mice (i.e., c-Cbl/ and Cbl-b/), and two mutant RING finger
knockins, i.e., c-Cbl(C379A) and Cbl-b(C373A). c-Cbl/, Cbl-
b/, and Cbl-b(C373A) mice breed successfully as homozy-
gous mutants, whereas analysis of c-Cbl(C379A) knockin mice
requires the generation of mice with a single mutated RING
finger allele and a null allele as most homozygous c-Cbl RING
finger mutant mice die in utero (Thien et al., 2005). These single
copy mutant mice, termed c-CblA/, are generated frommatings
between c-Cbl/ x c-CblA/+ mice. In this study, we use c-Cbl+/
littermates, aged matched wild-type (WT) c-Cbl+/+ mice, or
heterozygous c-CblA/+ mice as controls.
Analysis of bone marrow (BM) from 8-week-old Cbl mutant
mice revealed an expansion in the frequency of myeloid lineage
cells in c-Cbl/ and c-CblA/ mice which was not present in
either the Cbl-b/ mouse or the Cbl-b RING finger knockin
(Cbl-bA/A). This was evident by the greater proportion of
CD11b+ and Gr-1+ cells in the BM from both the c-Cbl mutants,
which was accompanied by a decrease in the numbers of red
blood cells (RBCs) and B-lineage cells (Figure 1A; data not
shown).
A consequence of the myeloid expansion in the marrow is
a splenic disorder in c-Cbl/ and c-CblA/ mice characterized
by increased hematopoiesis with an expanded red pulp caused
by increased numbers of infiltrating RBCs, monocytes, granulo-
cytes, and megakaryocytes (Figure 1B). However, the disruption
to splenic architecture and splenomegaly is clearly more pro-
nounced in c-CblA/mice compared with c-Cbl/mice (Figures
1B and 1C), suggesting that additional signaling perturbations,
beyond the loss of c-Cbl E3 ligase activity, are affecting hemato-
poiesis in this mouse. In contrast Cbl-b mutant mice had WT
levels of BM cell populations and structurally normal splenic folli-
cles and red pulp (Figures 1A and 1B).
Although c-Cbl/ mice develop a mild myeloproliferative
disorder (Murphy et al., 1998; Naramura et al., 1998; Sanada
et al., 2009; Thien et al., 2003), these animals fail to progress342 Cancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc.to a severe myeloid disease, even at later stages (2 years) of
life. In addition, neither Cbl-b/ nor Cbl-b RING finger mutant
mice develop any signs of hematologic proliferative disorders
as they age. In contrast survival of c-CblA/ mice was signifi-
cantly reduced through the development of myeloid leukemia.
Cohorts of c-CblA/ and c-Cbl+/ littermates were therefore
established for a detailed characterization of the disease.
Leukemia Development in c-Cbl RING Finger
Mutant Mice
All CblA/ mice in a cohort of 28 mice developed an aggressive
myeloid leukemia with the majority of mice succumbing within
the first year of life (Figure 2A). All mice show marked spleno-
megaly and significantly elevated white blood cell (WBC) counts
compared with their c-Cbl+/ littermates (Figures 2B and 2C).
Blood films and flow cytometry revealed a marked increase in
the numbers of promonocytes, monocytes, neutrophils, and, to
varying degrees, B lymphocytes (Figure 2E; Figure S1). The B
cell expansion, however, was not evident in the BM or spleen
(Figure S1), nor did the B-lineage cells invade the liver, kidneys,
or lungs where myeloid cells predominated. An example of a
leukemic c-CblA/ mouse is shown in Figure 2D. This mouse
showed an increase in the numbers of monocytes, neutrophils
and B lymphocytes in the blood (Figure 2E; Figure S1 see mouse
F10) and an extensive infiltration of monocytes into the spleen,
liver, kidney and lungs (Figure 2F). Immunophenotyping of BM,
spleen and blood confirmed the expansion of CD11b+ and
Gr-1+ cells (Figure 2G). In the spleen and BM this was accompa-
nied by a marked reduction in IgD+ B cells and an increase in the
proportion of immatureCD19+ IgD- cells in the spleen (Figure 2G).
A CD11b+ CD19+ population was also evident in the blood, and
to a lesser extent in the spleen, of some of the leukemic mice
(Figure 2G; Figure S1). This phenotype has been observed in
a subclass of aggressive human acute leukemias (Owaidah
et al., 2006). Approximately half the mice also exhibited varying
degrees of lymph node involvement due to an expansion of large
B-lineage cells (Figures S1C and S1D). These phenotypic char-
acterizations indicate the existence of leukemic progenitors
capable of differentiating along myeloid or B-lineage pathways.
However, this bipotential was only evident in blood and lymph
nodes whereas the splenic and BM environments promoted
the expansion of myeloid lineage cells. Furthermore, unlike
v-Cbl-induced malignancies (Langdon et al., 1989), no mice
solely developed pre-B cell lymphomas.
A number of studies have found heterozygous c-Cblmutations
in AML patients (Abbas et al., 2008; Caligiuri et al., 2007;Masashi
et al., 2008; Reindl et al., 2009; Rodrigues et al., 2008;
Sargin et al., 2007); however, while c-CblA/+ mice examined at
20–30 weeks of age showed mild signs of increased intrasplenic
hematopoiesis, none progressed to develop leukemia (data not
shown). The reason why heterozygous c-Cbl mutations can
contribute to the development of AML in humans, but not
mice, is not known; however, inmost cases the humanmutations
involve exon 8 or exon 8/9 deletions which have been found to
have enhanced oncogenic potential compared with point muta-
tions in the RING finger domain (Bandi et al., 2009; Reindl et al.,
2009; Thien et al., 2001). Furthermore, a heterozygous exon 8
deletion in c-Cbl has been identified in a NUP98-HOXD13 trans-
genic model of MDS that progressed to AML (Slape et al., 2008).
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Figure 1. Young Preleukemic c-Cbl Mutant
Mice Show an Expanded Population of
Myeloid Lineage Cells in Their BoneMarrow
and Increased Intrasplenic Hematopoiesis
(A) Bone marrow from 8-week-old Cbl-b WT (Cbl-
b+/+), Cbl-b(C373A) RING finger knockin mutant
(Cbl-bA/A), Cbl-b knockout (Cbl-b/), c-Cbl
heterozygous knockout (c-Cbl+/), c-Cbl(C379A)
RING finger knockin mutant (c-CblA/), and c-Cbl
knockout (c-Cbl/) mice were analyzed for
myeloid lineage cells by anti-CD11b and anti-
Gr-1 antibody staining and flow cytometry. Data
are representative of five independent experi-
ments.
(B) H&E-stained sections of spleens from young
mice (9–13 weeks) of the same genotypes as
above. The spleens from both c-Cbl mutant mice
show a disrupted architecture due to an expansion
of the red pulp which can be seen infiltrating the
splenic follicles. Scale bars, 1mm.
(C) Marked splenic enlargement in young c-Cbl
RING finger mutant mice (A/) compared with
WT littermates (+/) and c-Cbl knockout mice
(/).
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c-Cbl and Myeloid LeukemiaThis finding suggests that heterozygous c-Cbl mutations may be
more effective in promoting leukemogenesis when cells have
acquired an initiating mutation.Cancer Cell 18, 341–352,c-Cbl RING Finger Mutant LT-HSCs
Transfer MPD, and Leukemic
Phenotypes
A hallmark of leukemia initiating cells is
the ability to transfer the disease upon
transplantation into irradiated WT recip-
ient mice (Bonnet, 2005; Lapidot et al.,
1994; Wang and Dick, 2005). Therefore,
to address whether the MPD and leu-
kemic phenotypes of c-CblA/ mice are
transferable and cell intrinsic BM trans-
plantation studies were performed using
donor cells from preleukemic mice. Three
months after transplantation recipient
mice receiving c-CblA/ BM cells showed
evidence of myeloid leukemia develop-
ment (Figure 3A). To identify which hema-
topoietic populations are required for
leukemia development, we isolated BM
cells representing various developmental
stages of myelopoiesis from 8-week-
old c-CblA/+ and c-CblA/ mice. These
cells were then transplanted into suble-
thally irradiated RAG2-deficient congenic
recipient mice, as described earlier (Pas-
segue et al., 2004). While unfractionated
total BM cells always transferred the
disease, c-Kit-depleted BM did not,
suggesting that the leukemia initiating
cells reside in the hematopoietic progen-
itor compartment (Figure 3B). Transfer
of common myeloid progenitor (CMP),
granulocyte myeloid progenitor (GMP),CMP + GMP + megakaryocyte erythrocyte progenitor (MEP),
Gr1+CD11b+ cells, and splenocytes also did not result in the
development of leukemia (Figure 3B), although donor-derivedOctober 19, 2010 ª2010 Elsevier Inc. 343
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Figure 2. Characterization of c-CblA/– Leukemic Mice
(A) Kaplan-Meier survival plot showing reduced survival of c-CblA/mice compared with their corresponding c-Cbl+/ normal littermates. The median survival of
c-CblA/ mice was 47.5 weeks and the mean survival ± SD was 46.8 ± 13 weeks (n = 28).
(B) Spleen weights of c-CblA/ leukemic mice at the time of death compared with c-Cbl+/ littermate controls. Mean spleen weights ± SD are 103 ± 41 mg for
c-Cbl+/ mice and 1896 ± 1578 mg for c-CblA/ mice (n = 20). p = 0.0001 by two-sided unpaired t test.
(C) Increased white blood cell (WBC) counts of c-CblA/ leukemic mice at the time of death compared with c-Cbl+/ littermates. MeanWBC counts ± SD are 12 ±
7 3 109/liter for c-Cbl+/ mice and 81 ± 38 3 109/liter for c-CblA/ mice (n = 20). p < 0.0001 by two-sided unpaired t test.
(D) Photograph of a representative c-CblA/ leukemic mouse that succumbed to myeloid leukemia at 44 weeks of age. Note the splenomegaly and extensive
infiltration of leukemic cells into the liver. Enlarged inguinal and cervical lymph nodes are also evident.
(E) Diff-Quick stained blood smears showing monocytes, neutrophils, and lymphocytes in the blood from the 44-week-old c-CblA/ leukemic mouse shown in (D)
compared with its c-Cbl+/ normal littermate. Scale bar, 50mm.
(F) H&E stained tissue sections of spleen, liver, kidney, and lung from the c-CblA/ leukemic mouse shown in (D) showing extensive infiltration of leukemic cells
compared with its c-Cbl+/ littermate. Scale bar, 1mm.
(G) Immunophenotyping of a c-CblA/ leukemic mouse and its c-Cbl+/ littermate. Bone marrow (BM), spleen, and blood cells from a 44-week-old c-CblA/
leukemic mouse and its c-Cbl+/ littermate were analyzed by flow cytometry to determine forward and side scatter profiles and the proportions of
CD11b+,Gr-1+; CD11b+,CD19+, and CD19+,IgD+ cells. See also Figure S1.
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c-Cbl and Myeloid Leukemia(CD45.2+) hematopoiesis could be detected after 4 weeks of
transplantation (Figure S2). These results suggested that MPD
and leukemia development is dependent on the presence of
progenitors before the CMP stage. Interestingly, analysis of
recipients transferred with either long-term HSCs (LT-HSCs) or
short-term HSCs (ST-HSCs) + multipotent progenitors (MPPs)
revealed that the leukemia initiating cells requires the LT-HSC
compartment since it was only recipients that received LT-
HSCs from c-CblA/ mice that developed MPD and progressed344 Cancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc.to leukemia (Figure 3B). The inability of ST-HSCs and MPPs to
transfer the disease was not due to a lack of repopulating ability
as donor-derived myeloid lineage cells could still be detected up
to 6 months posttransplantation (Figure S2). In contrast, no
recipient mice that received LT-HSCs from heterozygous
c-CblA/+ mice developed MPD or leukemia (Figure 3B). Equiva-
lent results were obtained when hematopoietic fractions from
40-week-old leukemic c-CblA/ mice were transplanted into
sublethally irradiated RAG2-deficient recipients (Figure 3C),
Figure 3. Leukemia in c-Cbl Mutant Mice Is an HSC Disorder
(A) RBC-depleted BM (1 3 106) cells from 8-week-old c-CblA/+ and c-CblA/ mice (CD45.2+) were injected into lethally irradiated 8-week-old WT CD45.1+ con-
genic recipients. Three months after transplantation, donor-derived (CD45.2+) cells from BM (left) and spleen (right) were gated and analyzed for CD11b and Gr1
expression. WBC counts in the peripheral blood (bottom) of recipient mice were measured and indicated (mean ± SD; n = 5). Data are representative of two inde-
pendent experiments.
(B) Sublethally irradiated RAG2/ CD45.1 recipient mice were injected with the indicated numbers of fractionated donor BM subsets or splenocytes isolated
from 8-week-old c-CblA/+ and c-CblA/ (preleukemic) mice. Recipients were monitored monthly for up to 12 months, starting at 4 weeks after transplantation,
by flow cytometric and differential counts of peripheral blood. BM, spleen, liver, lungs, and kidneys were further analyzed by flow cytometry and histology to
determine leukemia development. All the data shown here were generated from an individual experiment. The data points were collected from each mouse
of the specified individual groups and presented. Data are representative of two independent experiments.
(C) Sublethally irradiated RAG2/ CD45.1 recipient mice were injected with the indicated numbers of fractionated donor BM subsets or splenocytes isolated
from 40-week-old c-CblA/+ and c-CblA/ (leukemic) mice. Recipients were monitored monthly for up to 12 months to determine leukemia development. All
the data shown here were generated from an individual experiment. The data points were collected from each mouse of the specified individual groups and pre-
sented. Data are representative of two independent experiments.
(D) A graph representing the kinetics of leukemia caused by the transfer of LT-HSCs obtained from 8-week-old preleukemic c-CblA/ mice (white bars) or
40-week-old leukemic mice (black bars). The data shown here were generated from an individual experiment and are representative of two independent exper-
iments.
(E) BM cells (1 3 106) from 8-week-old WT congenic (CD45.1) mice were injected into lethally irradiated 8-week-old c-CblA/+ and c-CblA/ (CD45.2) recipients.
Three months after transplantation, donor-derived (CD45.1+) cells of BM (left) and spleen (right) were gated and analyzed for CD11b and Gr1 expression. WBC
counts in the peripheral blood (bottom) of recipient mice were measured and indicated (mean ± SD; n = 5). Data are representative of two independent exper-
iments. See also Figure S2.
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c-Cbl and Myeloid Leukemiaalthough the latency was reduced compared with mice receiving
preleukemic LT-HSCs (Figure 3D).
These data provided proof that the leukemia initiating cells are
present within the hematopoietic compartment of the BM; never-
theless, pre-exposure of hematopoietic cells to the c-Cbl mutant
microenvironment might irreversibly alter their properties before
transplantation. Indeed, recent studies have shown that myeloid
leukemia can be caused by defects in the microenvironment
(Raaijmakers et al., 2010; Walkley et al., 2007). To test this possi-
bility, CD45.1 WT congenic BM cells were transplanted into
lethally irradiated c-CblA/ and c-CblA/+ recipients. Analysis after
12, 24, and 32 weeks of transplantation revealed no evidence ofCMPD or leukemia development in c-CblA/+ and c-CblA/ recipi-
ents (Figure 3E; data not shown).
Enhanced Receptor Tyrosine Kinase (RTK) Signaling
in CblA/– Hematopoietic Progenitors
c-Cbl is a negative regulator of RTK signaling through its E3 ubiq-
uitin ligase activity and c-Cbl mutations found in human leuke-
mias abolish this function (for review, see Kales et al., 2010;
Ogawa et al., 2010). Since myeloid malignancies involving
c-Cbl originate from hematopoietic precursors we focused on
signaling by c-Kit and FLT3, and the roles they may play in
promoting leukemia in c-CblA/ mice. To examine signalingancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc. 345
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Figure 4. Constitutive Activation of Akt in
Lineage-Negative Hematopoietic Cells
from c-CblA/– Mice
(A and B) Lineage negative BM cells from 7-week-
old c-Cbl+/, c-CblA/, and c-Cbl/ mice were
incubated in serum-free media for 1 hr at 37C.
The cells were either left unstimulated or stimu-
lated at 37C with SCF or FL at the concentrations
and times indicated. The cells were lysed in SDS
PAGE sample buffer and analyzed for the levels
of phospho-Akt(S473) by immunoblotting. The
blots were probed with anti-actin antibodies to
indicate the relative protein levels in each track.
Note the higher level of constitutively active Akt
in cells from the c-Cbl RING finger mutant mouse
which is sustained following SCF or FL stimulation.
(C) FL- and SCF-stimulated LSK cells from
c-CblA/ mice show sustained Erk activation.
Lineage negative bone marrow cells stimulated
with 25 ng/ml of SCF or 50 ng/ml of FL were
stained with anti-c-Kit, -Sca-1 and -phospho-Erk
antibodies and analyzed by flow cytometry. LSK
cells from c-CblA/ and c-Cbl/mice show phos-
pho-Erk levels that are sustained to equivalent
levels following SCF stimulation, whereas FL stim-
ulation revealed a markedly sustained signal
unique to c-CblA/ cells.
(D) BM cells from c-Cbl+/, c-CblA/, c-Cbl/, and c-CblF/F mice were enriched for myeloid lineage cells or lineage negative cells then incubated in serum-free
media for 1 hr at 37Cbefore analysis by immunoblotting with anti-c-Cbl phospho-tyrosine 737 or anti-c-Cbl antibodies. Of note is the higher level of constitutively
phosphorylated tyrosine 737 in the mutant RING finger protein compared with WT c-Cbl. Antibody specificity was confirmed by including cells from a mouse
expressing a Y737F knockin mutation (i.e., F/F) that is not recognized by antiphospho-Y737 antibodies. See also Figure S3.
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c-Cbl and Myeloid Leukemiaresponses, we purified lineage negative (Lin-) BM cells from
young preleukemic c-Cbl+/, c-CblA/, and c-Cbl/ mice and
stimulated them with either stem cell factor (SCF) or FLT3 ligand
(FL). Because of the marked activation of Akt in thymocytes from
c-CblA/ mice, but not c-Cbl/ mice (Thien et al., 2005, 2010),
we initially examined the activity of Akt. Immunoblotting with
anti-phospho-Akt antibodies revealed a higher level of constitu-
tive Akt activation in serum-starved Lin- BM cells from c-CblA/
mice compared with both c-Cbl+/ and c-Cbl/ mice (Figures
4A and 4B). Following stimulation with SCF, all three genotypes
showed an equivalent induction of phospho-Akt, but the Akt
signal was sustained in c-CblA/ cells (Figure 4A, see 30 min).
This sustained signal does not appear to be due to either
increased levels of c-Kit expression or a greater proportion of
c-Kit-positive cells since they were similar among the three
genotypes (Figure S3). Similar effects were seen following FL
stimulation where c-CblA/ cells showed a more sustained acti-
vation of Akt (Figure 4B). The enhanced induction of phospho-
Akt in c-CblA/ cells compared with both c-Cbl+/ and c-Cbl/
cells was more marked when a suboptimal concentration (5 ng/
ml) of FL was used suggesting a heightened sensitivity to FL-
stimulation (Figure 4B, lower panel). This greater level of stimula-
tion may in part be due to the presence of an expanded popula-
tion of FLT3high cells in c-CblA/mice (Figure S3). This population
is characterized in more detail in the subsequent section.
SCF and FL-induced activation of Erk was also analyzed, but
in this case by flow cytometry which enabled the examination of
LSK cells (Figure 4C). Unfortunately, attempts to detect phos-
pho-Akt induction by flow cytometry were unsuccessful there-
fore restricting our Akt analysis to immunoblotting as described
above. There was no detectable difference in constitutive phos-346 Cancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc.pho-Erk levels cells (Figure 4C, 0 min), and following 5 min of
SCF stimulation a large but equivalent induction of Erk was
observed in LSK cell from all three genotypes (Figure 4C).
However by 30 min c-CblA/ and c-Cbl/ LSK cells showed
a more sustained signal compared with wild-type cells. This
enhanced phospho-Erk signal in both c-Cbl mutants is con-
sistent with our findings in thymocytes following T cell receptor
stimulation (Thien et al., 2005). In contrast FL stimulation of
LSK cells led to a sustained phospho-Erk signal that was
only evident in c-CblA/ cells, whereas phospho-Erk levels in
c-Cbl+/ and c-Cbl/ LSK cells showed equivalent intensities
and kinetics (Figure 4C). This finding, along with the greater
responsiveness of c-CblA/ lineage negative cells to FL activa-
tion of Akt, provides evidence that heightened FLT3 signaling
may be a contributing factor that distinguishes the c-CblA/
mouse from the c-Cbl/mouse in their contrasting susceptibil-
ities to leukemia development.
Since activation of the PI3K/Akt pathway can be mediated by
an interaction between phospho-Y737 in c-Cbl and the SH2
domains of the p85 regulatory subunit of PI3K (Thien et al.,
2010), we examined the levels of phospho-Y737. Immunoblot-
ting of lineage negative and myeloid-enriched BM cells with
anti-phospho-Y737 antibodies revealed a greater fraction of
the mutant c-CblA/ protein was constitutively phosphorylated
on Y737 compared with WT c-Cbl (Figure 4D). This finding pro-
vides evidence that the mutant c-Cbl protein itself may be
contributing to the enhanced Akt signal as previously shown in
c-CblA/ thymocytes (Thien et al., 2005, 2010). Antibody speci-
ficity was confirmed by including cells from a mouse expressing
a Y737F knockin mutation (i.e., F/F) that is not recognized by
anti-phospho-Y737 antibodies (Thien et al., 2010).
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Figure 5. FL Deficiency in c-Cbl RING
Finger Mutant Mice Prevents the Develop-
ment of Leukemia
(A) Cohorts of c-Cbl+/ FLKO (n = 6), c-CblA/
FLKO (n = 7), Cbl+/ (n = 5), and CblA/ (n = 3)
mice were bled from the tail vein at the indicated
ages and WBC cells counts determined by
Hemavet analysis. By 52 weeks, two of the three
c-CblA/ mice had succumbed to leukemia com-
pared with none of the c-CblA/ FLKO mice. The
bar graphs represent mean WBC counts ± SD.
(B) Lineage negative BM cells from 25-week-old
Cbl+/, CblA/, and c-CblA/ FLKO mice were left
unstimulated or stimulated with FL for the indi-
cated times. Total cell lysates were analyzed by
immunoblotting with antiphospho-Akt, phospho-
Erk, and actin antibodies.
(C) BM cells from 8-week-old Cbl+/, CblA/, and
c-CblA/ FLKOmice were analyzed by flow cytom-
etry for the cell-surface expression of FLT3 on
LSK cells. Analysis of the percentages of FLT3high
LSK cells revealed 31%, 43%, and 5% for Cbl+/,
CblA/, and c-CblA/ FLKOmice, respectively. The
c-Cbl+/ FLKO littermate was also analyzed and
contained 6% FLT3high LSK cells indicating that
the c-CblA/ mutation is unable to rescue the
FLKO phenotype. See also Figure S4.
(D) BM cells from 6-week-old Cbl+/, CblA/, and c-Cbl/mice were analyzed by flow cytometry for the cell-surface expression of FLT3 on LSK cells. Analysis of
the percentages of FLT3high LSK cells revealed 33%, 50%, and 18% for Cbl+/, CblA/ and c-Cbl/ mice, respectively. See also Figure S4.
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of Leukemia in c-CblA/– Mice
Recent studies of hematopoietic cell lines coexpressing onco-
genic forms of c-Cbl and WT FLT3 have provided evidence
that patients with c-Cbl mutations may benefit from FLT3 tyro-
sine kinase inhibitor treatment (Reindl et al., 2009; Sargin et al.,
2007). In addition the findings that c-CblA/ hematopoietic
progenitors show greater responsiveness to FL stimulation (Fig-
ures 4B and 4C) are consistent with this hypothesis. Here, we
tested this via a genetic approach by mating c-Cbl RING finger
mutant mice with FLT3 ligand-deficient mice (i.e., FLKO mice)
(McKenna et al., 2000). By monitoring cohorts of double
and single mutant mice, we found that the FL deficiency in
c-CblA/ mice caused a marked reduction in peripheral WBC
counts (Figure 5A), an effect that was evident in both the B and
myeloid lineages (Figure S4). Furthermore, in striking contrast
to c-CblA/ mice where two of the three mice in this cohort
succumbed to leukemia by 52 weeks, none of the seven double
mutant mice showed any signs of leukemia development. Anal-
ysis of liver, kidney, and lung sections at 52 weeks also revealed
that the loss of FL prevented myeloid cell invasiveness
(Figure S4). The FL deficiency, however, did not completely
circumvent increased intrasplenic hematopoiesis and spleno-
megaly, although it was reduced compared with c-CblA/ mice
(Figure S4). Representative FACS profiles show the extent of
myeloid lineage expansion in the spleens of both c-CblA/ and
c-CblA/ FLKO (Figure S4).
Constitutive activation of Akt Is Suppressed in c-CblA/–
FLKO Progenitors
To determine whether the FL deficiency in c-CblA/mice affects
signaling in hematopoietic progenitors, we examined the activityCof Akt and Erk. Immunoblotting of lysates from Lin- cells with
phospho-Akt antibodies revealed a reduced level of constitu-
tively active Akt in cells from c-CblA/ FLKO mice compared
with c-CblA/mice (Figure 5B). This suggests that FLT3 signaling
contributes to the enhanced constitutive activation of Akt in
hematopoietic progenitors from c-CblA/ mice, and that this
signal may be involved in promoting the MPD. Furthermore
following stimulation with FL the Lin- cells from c-CblA/ FLKO
mice did not activate Akt or Erk to the levels observed in
c-CblA/ cells suggesting a deficiency in a FLT3-responsive pop-
ulation. Indeed, examination of LSK cells from c-CblA/ FLKO
mice revealed a marked reduction in cells expressing high levels
of FLT3 (Figure 5C). In contrast LSK FLT3high cells are expanded
in c-CblA/ mice compared with cells from WT c-Cbl+/ mice
(Figure 5C). Thus, the decreased responsiveness of c-CblA/
FLKO Lin- cells to FL stimulation compared with c-CblA/ cells
appears to be due to markedly different proportions of FLT3high
cells. It is intriguing, however, that in spite of the low level of FLT3
expression on c-CblA/ FLKO cells the FL-induced Akt signal
remains more intense compared with c-Cbl+/ cells which
have a higher proportion of the FLT3high population. Thus, the
enhanced Akt signal in cells expressing the RING finger domain
mutation is not solely a consequence of increased RTK levels.
c-Cbl Knockout Mice Are Deficient in FLT3high LSK Cells
The finding that the prevention of leukemia in c-CblA/ FLKO
mice correlates with a marked reduction in the numbers of
FLT3high LSK cells suggests these cells may be involved in
disease development. We therefore examined whether resis-
tance to leukemia in c-Cbl/micemay also be linked to a pertur-
bation in FLT3high LSK cells. Strikingly, we found that in c-Cbl/
mice this population is markedly reduced (Figure 5D). From fourancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc. 347
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7
Signal
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8 Transcription 14 10 24 
9
Cytoskeleton/ Cell 
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11 Proliferation 6 5 11 
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14 Apoptosis 3 3 6 
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16 Chemotaxis 3 0 3 
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Figure 6. Genome-wide Transcriptional Profiling Assays Identify Deregulated Expression of Genes in c-CblA/– Hematopoietic Stem and
Progenitor Cells
(A) Diagram representing the total number of upregulated and downregulated genes in c-CblA/ LT-HSCswhen comparedwith c-Cbl+/+ LT-HSCs. Transcriptional
profiling analysis was performed on highly purified (>98%) LT-HSCs obtained from the BM of 8-week-old c-Cbl+/+ and c-CblA/ mice.
(B) The Gene Ontology (GO) analysis. Genes that were differentially expressed in LT-HSCs of c-CblA/ mice were subjected to the GO analysis to identify the
major clusters of genes. Differentially expressed genes were grouped either based on their involvement in a specific biological process or based on its molecular
functions. Indicated are the numbers (#) of upregulated and downregulated genes under each major category listed.
(C) List of transcription factors that were upregulated (left) and downregulated (right) in c-CblA/ LT-HSCs when compared with c-Cbl+/+ LT-HSCs.
(D) Diagram representing the total number of upregulated and downregulated genes in c-CblA/ LT-HSCs when compared with c-Cbl/ LT-HSCs.
(E) List of transcription factors that were upregulated (left) and downregulated (right) in c-CblA/ LT-HSCs when compared with c-Cbl/ LT-HSCs.
(F) List of total number of upregulated and downregulated genes in ST-HSCs, MPPs, CMPs, GMPs, and MEPs of c-CblA/ mice when with to the respective
progenitor subsets of c-Cbl+/+ mice. See also Figure S5 and Tables S1–S4.
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average of 18.5% FLT3high LSK cells in c-Cbl/mice compared
with 31.5% and 50.8% in c-Cbl+/ and c-CblA/ mice, respec-
tively. This finding not only further implicates this population as
playing a role in the development of c-Cbl-associated leukemia
but also suggests that signaling by WT c-Cbl may be involved
in the generation and/or maintenance of cells with a phenotype
that consistent with that of multipotent progenitors.
Transcription Profiling of c-Cbl Mutant HSCs
Intensive research in recent years has provided many clues
about the biology of the transformation of HSC to leukemic
stem cells (LSCs) but, nevertheless, the molecular mechanisms
that promote this transformation remain poorly understood
(Steidl et al., 2006). We therefore carried out a genome-wide
transcriptional profiling of LT-HSCs from 8-week-old preleuke-
mic c-CblA/ and c-Cbl+/+ mice in an attempt to identify these348 Cancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc.molecular events. Using the Illumina microarray system, we
identified 297 upregulated and 209 downregulated genes in
c-CblA/ LT-HSCs when compared with LT-HSCs of c-Cbl+/+
mice (Figure 6A; Table S1). To obtain insights into which molec-
ular pathways are deregulated, a Gene Ontology (GO) analysis
was performed. This revealed several major clusters of genes
that are deregulated in c-CblA/ LT-HSCs. These include genes
involved in ion transport, immune responses, metabolism,
membrane proteins, protein turnover, chromatin modification,
signal transduction, and transcription factors (Figure 6B; Table
S2). Intriguingly, our analysis identified a remarkable bias in the
downregulation of genes associated with chromatin modifica-
tion compared with those that are upregulated, i.e., 24 to 1,
respectively (Figure 6B; Table S2). In light of this, it is tempting
to speculate that significant changes in chromatin architecture
and assembly might be associated with the transformation of
normal HSCs of c-CblA/ mice.
Table 1. Testing the Involvement of Individual Candidate Transcription Factors in the Development of Myeloid Leukemia
Sample No. Candidates Approach No. of Cells No. of Mice
Observation (Months)
3 6 9 12
1 Id1 Knockdown 500,000 10 0/10 6/10 9/10 10/10
2 Hes1 Knockdown 500,000 10 0/10 5/10 10/10 10/10
3 Fosl2 Knockdown 500,000 10 0/10 6/10 10/10 10/10
4 Pml Knockdown 500,000 10 0/10 2/10 6/10 8/10
5 JunB Overexpression 500,000 10 0/10 7/10 10/10 10/10
6 Klf2 Overexpression 500,000 10 0/10 5/10 8/10 10/10
7 GFP Control 500,000 10 0/10 6/10 9/10 10/10
The expression of candidate transcription factors in c-CblA/ LT-HSCs was modulated either by shRNA-mediated knockdown (Id1, Hes1, Fosl2, Pml)
or by retroviral-mediated overexpression (JunB and Klf2). Cells transduced with empty vector (IRES-GFP) served as controls. Two days after trans-
duction, 53 105 GFP+ cells were sorted and injected into sublethally irradiated RAG2-deficient animals. Recipients were observed and evaluated for
the development of leukemia as described in Figure 3B for up to 12 months. See also Figure S6.
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c-Cbl and Myeloid LeukemiaTranscription factors (TFs) represent the nodal point in the
control of hematopoiesis (Shivdasani and Orkin, 1996) and are
believed to be the master regulators that determine hematopoi-
etic cell fate (Bonnet, 2005). Hence, we aimed to identify the TFs
that are differentially expressed in c-Cbl mutant LT-HSCs. Our
microarray analysis revealed 14 upregulated and 10 downregu-
lated TFs in c-CblA/ LT-HSCs when compared with c-Cbl+/+
LT-HSCs (Figure 6C; Tables S1 and S2). Validation by real-
time quantitative PCR confirmed the differential expression
of ten of the upregulated and five of the downregulated TFs
(Figure S5A and S5B). Strikingly, 12 of these differentially ex-
pressed TFs, i.e., Fosl2, Per1, Pml, Id2, Id1, Hoxb5, Rorc,
Hes1, Fus, Klf2, JunB, and Egr1 are associated with the onset
or development of hematopoietic neoplasms.
In view of the differing phenotypes between c-Cbl/ and
c-CblA/ mice, we hypothesized that the gene expression
profiles might also be dissimilar between their LT-HSCs. Strik-
ingly, a direct comparison between c-CblA/ and c-Cbl/
LT-HSCs revealed differential expression of 474 genes (354
upregulated and 120 downregulated) (Figure 6D; Table S3)
which included upregulation of 14 TFs and downregulation
of 5 TFs (Figure 6E; Table S3). Interestingly, 8 of the 14 TFs,
i.e., Supt16h, Taf6, Id2, Pml, Lbh, Id1, Fosl2, and Rorc,
are commonly upregulated, and 2 of 5 TFs, i.e., Zfp367 and
JunB, are commonly downregulated in c-CblA/ LT-HSCs
when compared with both c-Cbl+/+ and c-Cbl/ LT-HSCs (Fig-
ure S5). However, 13 TFs (6 upregulated and 7 downregulated)
are differentially expressed in c-CblA/ cells when compared
only with c-Cbl+/+ cells (Figure S5C). Taken together, these
results reveal that c-CblA/ and c-Cbl/ LT-HSCs have very
distinct molecular signatures and these might explain the differ-
ences in the phenotypes observed between c-CblA/ and c-
Cbl/ mice.
In addition, we investigated whether the deregulated gene
expression observed in the LT-HSCs of c-CblA/ mice changed
the expression profile of downstream progenitors. Transcrip-
tional profiling of purified ST-HSCs, MPPs, CMPs, GMPs, and
MEPs revealed that a total of 175 genes in ST-HSCs, 331 genes
in MPPs, 104 genes in CMPs, 368 genes in GMPs, and 278
genes in MEPs were differentially expressed in c-CblA/ hemato-
poietic progenitors when compared with the same of c-Cbl+/+
mice (Figure 6F; Table S4; data not shown).CModulating the Expression of Individual Candidate TFs
Does Not Affect c-Cbl-Directed Leukemia
To investigate whether changes in the expression of individual
TFs might be essential for the c-CblA/ phenotype, we examined
the effects of shRNA-mediated knockdown or retroviral-medi-
ated overexpression of selected TFs. We chose TFs that are
associated with leukemogenesis and are overexpressed in
c-CblA/ LT-HSCs, such as Pml, Id1, Hes1, and Fosl2, as candi-
dates for the knockdown studies and TFs that are downregu-
lated in c-CblA/ LT-HSCs such as JunB and Klf2 as candidates
for overexpression studies. The effectiveness of the knockdown
or overexpression of these genes and the repopulating efficiency
is shown in Figure S6. Interestingly, we found that neither the
knockdown nor overexpression of these TFs prevented the
development of leukemia (Table 1), although knockdown of
Pml did delay the onset (Table 1). This effect, although not
profound, is of interest in light of the requirement of Pml for the
maintenance of both HSCs and LSCs (Ito et al., 2008). These
data support the notion that an array of TFs contribute to the
phenotype of c-CblA/ mice; however, the targeting of these
genes in isolation is unlikely to be an effective approach in retard-
ing leukemia development.
Taken together, the transcriptional profiling data suggest that
the dynamic balance of a regulatory network of many pathways
is determining the leukemic transformation of normal HSCs to
LSCs. Although the transcriptional profiling has identified genes
that may promote a heightened probability of further genetic
changes within c-CblA/ LT-HSCs, further studies are required
to delineate the precise molecular control of leukemogenesis
mediated by the c-Cbl RING finger mutant protein.
DISCUSSION
This study represents a detailed characterization of an in vivo
model for c-Cbl-associated MPNs. We demonstrate that the
c-Cbl RING finger mutant mouse permits the analysis of
signaling events in hematopoietic progenitors that promote
susceptibility to leukemia as well as providing a means for iden-
tifying additional genetic changes that lead to leukemia. Impor-
tantly, this mouse provides a way for testing the efficacy of
compounds that target signaling pathways that are altered as
a consequence of c-Cbl RING finger domain mutations.ancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc. 349
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c-Cbl and Myeloid Leukemiac-Cbl was identified to function as a negative regulator of RTK
signaling through genetic studies inC. elegans (Yoon et al., 1995)
and the biochemistry was determined soon after by landmark
studies identifying c-Cbl and other family members as E3 ubiq-
uitin ligases that target RTKs (Joazeiro et al., 1999; Levkowitz
et al., 1999). With the widespread involvement of RTKs in human
tumorigenesis, it is surprising that a decade passed before c-Cbl
mutations were found in human cancers. These cancers have
so far been restricted to MPNs and more recently lung cancers
(Tan et al., 2010). In this study, we characterize an MPD that
invariably leads to a lethal myeloid leukemia in the c-Cbl RING
finger mutant mouse. In contrast, the c-Cbl/ mouse develops
a mild MPD that does not lead to leukemia. This is consistent
with no c-Cbl null mutations being found in human tumors. The
more profound effects of retaining the mutant c-Cbl protein, as
opposed to a complete loss, raises the interesting question of
whether the c-Cbl mutant protein is principally functioning as
a dominant negative for Cbl-b or as a constitutively active onco-
gene, or indeed both. Although addressing this question is
beyond the scope of this study, a recent publication concluded
that mutations that result in the loss of E3 ligase activity in human
MPNs also result in a gain-of-function consistent with that of an
oncogene (Sanada et al., 2009). While our findings here and in
earlier studies are consistent with this idea, we believe that the
profound phenotype of the c-Cbl RING finger mutant mouse is
probably the combination of a block to Cbl-b compensation as
well as the provision of a highly phosphorylated signaling plat-
form that activates the PI3K pathway.
Given c-Cbl’s role as a negative regulator of RTK signaling, it is
significant that we identified FLT3 as a key component in
promoting c-Cbl-associated MPD and leukemia. Activating
mutations in FLT3 are common in human leukemias (Stirewalt
and Radich, 2003) and WT FLT3 attains an ‘‘activated’’ pheno-
type when coexpressed with oncogenic forms of c-Cbl (Reindl
et al., 2009; Sargin et al., 2007). Thus, it was encouraging that
the predictions from in vitro experiments were translated to an
animal model where FLT3 signalingwas enhanced in hematopoi-
etic progenitors. Consistent with this, we prevented the develop-
ment of MPD and leukemia in the c-Cbl RING finger mouse by
mating to FL knockout mice, thus providing credence for the
use of FLT3 kinase inhibitors as a potential therapy for c-Cbl-
associated leukemias. Equally hopeful may be the effectiveness
of inhibitors of the PI3K pathway since a downstream conse-
quence of enhanced FLT3 signaling by the c-Cbl mutant protein
is the constitutive and sustained activation of Akt in hematopoi-
etic progenitors.
Importantly, we also identified LT-HSCs as being the sole pop-
ulation of cells capable of transferring both the preleukemicMPD
and the leukemic phenotype to irradiated WT recipients. In
contrast, ST-HSCs and MPPs from preleukemic or leukemic
mice do not have this capability. This is an intriguing finding in
view of the unique phenotype of the c-Cbl RING finger mutant
mouse with its expanded population of FLT3high LSK cells,
a phenotype that defines MPPs (Yang et al., 2005). So although
this expanded population correlates with MPD and leukemia
development, these cells alone are insufficient to cause disease.
Nonetheless it is striking that the LSK FLT3high population is
reduced in both c-Cbl/ mice and c-CblA/ mice on a FLKO
background neither of which develop leukemia. Thus, the350 Cancer Cell 18, 341–352, October 19, 2010 ª2010 Elsevier Inc.evidence supports a key requirement for the FLT3high population
in c-Cbl-directed leukemogeneis; however, the biochemical
changes in these cells that are caused by the c-Cbl mutation
are alone insufficient to promote a long-term repopulating capa-
bility.
An additional consequence of the c-Cbl RING finger mutation
is the deregulated expression of many genes in LT-HSCs
compared with genes in WT and c-Cbl/ LT-HSCs. Because
of the large number of genes identified, it was feasible to only
focus on a select few and determine whether they play a causa-
tive role in promoting leukemia in c-Cbl RING fingermutant mice.
We therefore selected transcription factors that were differen-
tially regulated in c-CblA/ LT-HSCs compared with either
c-Cbl+/+ or c-Cbl/ LT-HSCs in addition to having a known
association with leukemia development. Other than a modest
effect of Pml knockdown none of the genes, when either
knocked down or overexpressed in c-CblA/ HSCs, were able
to suppress the development of leukemia in transplanted recip-
ients. Clearly, there is a limitation in these experiments to pre-
cisely revert the expression of transcription factors to WT levels;
however, the results do suggest that identifying and targeting
individual transcription factors with causative roles will be a diffi-
cult task. Indeed, it is more likely that a collaboration of several
transcription factors and other signaling molecules are involved
in promoting the heightened susceptibility to leukemia.
In conclusion, this study has provided a detailed characteriza-
tion of a preclinical murine model for c-Cbl-associated MPNs
and has set the stage for the use of this model to identify
compounds that will provide the best possible options for effec-
tive treatments.
EXPERIMENTAL PROCEDURES
Mice
The generation of c-Cbl/, c-Cbl(C379A), Cbl-b/, Cbl-b(C373A), and c-Cbl
(Y737F) mice have been previously described (Bachmaier et al., 2000; Murphy
et al., 1998; Oksvold et al., 2008; Thien et al., 2005, 2010). FLT3 ligand
knockout mice were purchased from Taconic (Hudson, NY) and were originally
generated in the laboratory of Dr. Jacques Peschon (McKenna et al., 2000). For
transplantation studies, RAG2/ mice on a CD45.1 congenic background
were used. All mice were maintained on a C57BL/6 background with the
exception of c-Cbl/ mice that were maintained on a mixed C57BL/6J
x129Sv/J background. All mouse experiments were approved and performed
in accordance with the guidelines and regulations of the Animal Ethics
Committee at the University of Western Australia (approval 07/100/578) and
the Institutional Animal Care and Use Committee of Yale University (IACUC).
Mice were housed under pathogen-free conditions in microisolator cages at
animal facilities at the University of Western Australia and Yale University.
Mice were monitored three times per week by visual inspection and palpation
and monthly by peripheral blood analysis. Blood was collected from the tail
vein and white blood cell counts determined using a Beckman Coulter
LH750 counter. Differential blood count analysis was performed using the
Hemavet 950 LV system (DREW Scientific, Waterbury, CT). Nucleated blood
cells were further characterized by phenotyping with lineage-specific
antibodies and flow cytometry (see Supplemental Experimental Procedures),
and blood films were stained by an automated Diff Quick procedure. Follow-
ing sacrifice mice were photographed and visually examined for tumor
development.
Transplantation Studies
For BM transplantation studies, 13 106 RBC lysed BM cells of either c-CblA/+
or c-CblA/micewere transplanted intravenously into lethally irradiated (11Gy)
CD45.1 congenic recipients. Alternatively, 1 3 106 RBC lysed BM cells of WT
Cancer Cell
c-Cbl and Myeloid LeukemiaCD45.1 congenic mice were transplanted into lethally irradiated c-CblA/+ or
c-CblA/ CD45.2 recipients. For HSC and progenitor transplantation studies,
sublethally (5.5 Gy) irradiated RAG2/ CD45.1 recipient mice were injected
with fractionated donor BM subsets (see Supplemental Experimental Proce-
dures) isolated from either 8- or 40-week-old c-CblA/+ and c-CblA/ mice.
Recipients were monitored monthly for up to 12 months, starting at 4 weeks
after transplantation, by flow cytometric and differential blood count analyses
of peripheral blood.Immunoblotting
Lineage-negative BM cells purified using a hematopoietic progenitor cell
enrichment kit (BD Biosciences) were incubated for 1 hr in serum-free IMDM
medium at 37C before stimulation with recombinant mouse SCF or FLT3
ligand (R&D Systems). The stimulation was terminated by the addition of
SDS sample buffer and cell lysates examined by immunoblotting with anti-
phospho-Akt(Ser473), anti-phospho-Erk1/2(T202/Y204), anti-phospho-c-Cbl
(Y731) (Cell Signaling Technology), anti-c-Cbl (Upstate Biotechnology), or
anti-Actin (Sigma) antibodies.Statistical Analysis
Data are presented as mean ± SD. Statistical significance was assessed using
a two-sided unpaired Student’s t test. p values >0.05 were considered to be
nonsignificant and p values <0.05 were considered to be significant.Microarray Studies
Transcription profiling studies were conducted using the Illumina MouseWG-6
v2.0 BeadChips arrays (Illumina Inc., San Diego, CA) according to the manu-
facturer’s instruction at the Keck microarray facility, Yale University. In brief,
labeled cRNA for hybridization onto Illumina BeadChips was prepared using
a TotalPrep RNA Amplification kit (Applied Biosystems). Double stranded
cDNA and biotin-labeled cRNA were synthesized and purified from 500 ng
of total RNA. cRNA was purified and the integrity of cRNA was assessed by
running aliquots on the Bioanalyzer prior to hybridization. Hybridization buffer
from the BeadChip kit (Illumina) was mixed with 1500 ng of biotin-labeled
cRNA, heated to 65C for 5 min, and then loaded onto the BeadChip. After
hybridization at 58C for 16–20 hr, the BeadChips were washed and stained
in a series of washes and stains as outlined in the Illumina protocol. Finally,
the BeadChips were scanned on the Illumina BeadArray Reader and analyzed
using the BeadStudio software. Quality control parameters were checked for
all arrays and the data normalized for background. The Gene Ontology (GO)
analysis was performed using the Gene spring GX (Agilent Technologies)
and the online AmiGO (AmiGO Version: 1.7) software. Differentially expressed
genes were classified under major trees based on their molecular functions.ACCESSION NUMBERS
The microarray data have been deposited in NCBI GEO under accession
number GSE23564.SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures, six figures, and
four tables and can be found online at doi:10.1016/j.ccr.2010.09.008.
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